CD109 Antigen (CD109) Antibody (FITC)

Background

CD109 molecule is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein that plays a role in regulating various cellular processes, including immune response and hematopoiesis CD109 is expressed on a variety of cells, including T-cells, endothelial cells, and platelets, and functions as a negative regulator of the transforming growth factor-beta (TGF-β) signaling pathway, which is critical for cell proliferation, differentiation, and immune response modulation By interacting with TGF-β receptors, CD109 modulates TGF-β signaling, potentially inhibiting excessive fibrosis or immune suppression Dysregulation of CD109 expression has been linked to certain cancers, where it can enhance tumor cell survival by suppressing anti-tumor immune responses It is also associated with autoimmune diseases, where its role in immune modulation can influence the development of inflammatory conditions Recent studies have explored CD109 as a potential biomarker for various diseases, including cancer and autoimmune disorders, emphasizing its importance in cellular regulation and immune homeostasis